Literature DB >> 7232854

Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32.

R H Blum, M B Garnick, M Israel, G P Panellos, I C Henderson, E Frei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7232854     DOI： 10.1007/978-3-642-81565-2_2

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


× No keyword cloud information.
  8 in total

Review 1.  Valrubicin.

Authors:  S V Onrust; H M Lamb
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

2.  Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder.

Authors:  Michael S Cookson; Sam S Chang; Christine Lihou; Thomas Li; Samira Q Harper; Zhihui Lang; Ronald F Tutrone
Journal:  Ther Adv Urol       Date:  2014-10

3.  Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study.

Authors:  T W Sweatman; R F Parker; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 4.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

5.  Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent.

Authors:  Sunil Shah; Rahul Chib; Sangram Raut; Jaclyn Bermudez; Nirupama Sabnis; Divya Duggal; Joseph D Kimball; Andras G Lacko; Zygmunt Gryczynski; Ignacy Gryczynski
Journal:  J Photochem Photobiol B       Date:  2015-12-18       Impact factor: 6.252

6.  Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.

Authors:  E Frei; S A Holden; R Gonin; D J Waxman; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.

Authors:  Jeffrey M Ignatoff; Yu-Hui Chen; Richard Evan Greenberg; Julio M Pow-Sang; Edward M Messing; George Wilding
Journal:  Urol Oncol       Date:  2008-07-17       Impact factor: 3.498

8.  Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32). Comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine.

Authors:  M Israel; A M Karkowsky; W J Pegg
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.